Skip to content

Sarah Ross

Sarah Ross

Company: AstraZeneca, Early Oncology TDE

Job title: Team Leader & Lead Bioscientist

Bio:

I am a team leader and lead bioscientist in the Early Oncology TDE group at AstraZeneca and have worked across a wide variety of projects within our small molecule and biologics oncology portfolio. Over the last 5 years I have been focused on drug discovery projects which directly target Ras1 and was significantly involved in a collaboration which developed a potent and selective next-generation clinical KRAS antisense oligonucleotide 2, 3. More recently I have been working on developing small molecule targets of oncogenic Ras.

  1. Chakraborty A, Linnane E, Ross S. Ras proteins as therapeutic targets. Biochem Soc Trans. 2018;46(5):1303-11.
  2. Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, et al. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Sci Transl Med. 2017;9(394).
  3. Linnane E, Davey P, Zhang P, Puri S, Edbrooke M, Chiarparin E, et al. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Res. 2019.

 

Seminars:

Developing Small Molecule Inhibitors of KRASG12C 11:30 am

Discovery of novel G12C inhibitors Overview of activity in preclinical disease models Building an understanding of what mediates sensitivity/resistance to G12C inhibitorsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.